Literature DB >> 10625687

p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor.

H Xiao1, T Hasegawa, K Isobe.   

Abstract

We have reported that histone acetylation induced by trichostatin A (TSA) promotes p21(waf1/cip1) (p21) expression, the GC-box located just upstream of TATA box was responsible for TSA-induced promoter activation, and both Sp1 and Sp3 were the working activator of this GC-box. To understand the molecular pathway from histone acetylation to this Sp1 family factors-mediated promoter activation, we investigated the function of p300, one of the histone acetyltransferase, in the present work. The evidence supporting the linkage between p300 and TSA-induced p21 promoter activation were realized from the following findings: 1) cotransfection of p300 elevated p21 promoter activity, and this elevation was dependent on TSA-responsive GC-box; 2) TSA-induced promoter activation was blocked by the introduction of p300 dominant-negative mutant into cells; and 3) Sp1- or Sp3-mediated activation was also suppressed by this p300 dominant-negative mutant. Our data also suggested that p300 collaborates with Sp1 in a way which is different from that when p300 collaborates with p53 in p21 transcription.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10625687     DOI: 10.1074/jbc.275.2.1371

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites.

Authors:  T Ragoczy; G Miller
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5.

Authors:  Anne Rascle; James A Johnston; Bruno Amati
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

3.  Sp3 proteins negatively regulate beta myosin heavy chain gene expression during skeletal muscle inactivity.

Authors:  Gretchen Tsika; Juan Ji; Richard Tsika
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

4.  Nordihydroguaiaretic acid inhibits growth of cervical cancer SiHa cells by up-regulating p21.

Authors:  Peng Gao; Fei Zhai; Lei Guan; Jie Zheng
Journal:  Oncol Lett       Date:  2010-11-10       Impact factor: 2.967

5.  A novel function of RNAs arising from the long terminal repeat of human endogenous retrovirus 9 in cell cycle arrest.

Authors:  Lai Xu; Abdel G Elkahloun; Fabio Candotti; Andrzej Grajkowski; Serge L Beaucage; Emanuel F Petricoin; Valerie Calvert; Hartmut Juhl; Frederick Mills; Karen Mason; Neal Shastri; Josh Chik; Cynthia Xu; Amy S Rosenberg
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

6.  Histone deacetylase inhibitors stimulate mitochondrial HMG-CoA synthase gene expression via a promoter proximal Sp1 site.

Authors:  Nuria Camarero; Alícia Nadal; María José Barrero; Diego Haro; Pedro F Marrero
Journal:  Nucleic Acids Res       Date:  2003-03-15       Impact factor: 16.971

Review 7.  Nf-kappa B, chemokine gene transcription and tumour growth.

Authors:  Ann Richmond
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

Review 8.  Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.

Authors:  Shuyang Chen; Nianli Sang
Journal:  J Biomed Biotechnol       Date:  2010-12-05

9.  Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter.

Authors:  Wei-Guo Zhu; Kanur Srinivasan; Zunyan Dai; Wenrui Duan; Lawrence J Druhan; Haiming Ding; Lisa Yee; Miguel A Villalona-Calero; Christoph Plass; Gregory A Otterson
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

10.  Remodeling of chromatin structure within the promoter is important for bmp-2-induced fgfr3 expression.

Authors:  Fenyong Sun; Qiongyu Chen; Songhai Yang; Qiuhui Pan; Ji Ma; Yang Wan; Chih-Hao Chang; An Hong
Journal:  Nucleic Acids Res       Date:  2009-04-28       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.